Strontium Ranelate is an antiosteoporotic agent that reduces bone resorption and promotes bone formation, leading to a positive bone balance. It activates the calcium-sensing receptor (CaSR) in non-skeletal cells, initiating inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling. For research use only.
- Reduces bone resorption and promotes bone formation.
- Induces a positive bone balance.
- Activates calcium-sensing receptor (CaSR) in non-skeletal cells.
- Increases early and late osteoblast markers (ALP, OCN) in mouse calvaria cells in vitro.
- Increases alkaline phosphatase activity and prostaglandin E2 production.
- Increases bone mass in vertebrae and lumbar/femur in adult mice and rats in vivo.
- Decreases bone resorption and increases bone formation in alveolar bone.
- Prevents trabecular bone loss in ovariectomized rats, improving bone strength.